You are here

Takeda Pharmaceuticals

Member Since 2008

Christophe Bianchi, MD

President, Global Oncology Business Unit

Christophe Bianchi, MD, is President of the Takeda Global Oncology Business Unit, a position he has held since October 2014. In his current role, Dr. Bianchi is responsible for oncology business activities in seven countries, including the U.S., Japan, U.K., Germany, France, Brazil and Indonesia.

Dr. Bianchi has more than 17 years of pharmaceutical industry experience and has held executive positions with Sanofi-Aventis and Millennium Pharmaceuticals. During his career, he has built commercial and sales organizations, launched major brands, delivered sustained growth and managed collaboration with partner companies.

Dr. Bianchi joined Millennium in 2006 where he was responsible for growing the company’s commercial and sales organizations and overseeing all commercial and sales activities for VELCADE®.

At Sanofi, Dr. Bianchi led the $2 billion U.S. oncology business unit including Eloxatin® and Taxotere. Previously at Sanofi-Synthelabo, Dr. Bianchi headed the internal medicine and central nervous system business unit with sales of $1.2 billion. Dr. Bianchi also spent more than 10 years at Rhone-Poulenc Rorer, where he last served as Vice President, Head of Global Marketing and led many of the commercial efforts for the antithrombotic, Lovenox®.

Dr. Bianchi received his medical degree from the University of Reims-Champagne in France, and an MBA from the Wharton School at the University of Pennsylvania in the U.S.

CEO Cancer Gold Standard™

Gold Standard  Employer

Since 2009

Gold Standard  Task Force Participation

Task Force Member(s): Nancy M. Shostack, Director, Head of Benefits and Mobility

Life Sciences Consortium

LSC  Task Force Participation

Task Force Member(s): Dean Bottino, PhD, Clinical Translational Modeling & Simulation Leader; Patrick Cullinan, PhD Head of Scientific Advocacy and Clinical Transparency Global Patient and Scientific Affairs Takeda Pharmaceuticals

Project Data Sphere, LLC

an independent initiative of the Life Sciences Consortium

Data Provider

Since 2017

Takeda Pharmaceuticals

At Takeda Oncology, the oncology business unit brand of Takeda Pharmaceutical Company Limited, we endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients.

This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, we are finding innovative ways to improve the treatment of cancer.

We've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though we've made great strides in our fight against cancer, we are determined to do more — to work harder and to reach higher. We continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that we are today.

We know that our mission is not a quick or simple one, but we are up to the task: we aspire to cure cancer.